title: Involvement of CD5+CD19+Cell in steroid-dependent nephrotic syndrome treated with B-cell targeting therapy.
abstract: We showed in this study the longitudinal changes of the B-cell counts in patients with steroid-dependent nephrotic syndrome (SDNS) treated with cyclophosphamide (CPM) and mycophenolate mofetil (MMF). In our case with SDNS, this combined therapy not only decreased B-cell counts but also increased CD5(+) CD19(+) (CD5(+) B)/ CD5(-) CD19(+) (CD5-B) cell ratio. Recurrence was not observed when an elevated CD5(+) B/CD5⁻B [corrected] cell ratio was maintained even after the B cells increased. Therefore, this ratio might be more important than the whole B-cell counts. The changes of this ratio could be a good predictor of the clinical course of the patients treated with B-cell targeting therapy.
authors: Department of Pediatrics, Uwajima City Hospital Department of Pediatrics, Ehime Prefectural Imabari Hospital Department of Pediatrics, Ehime Prefectural Central Hospital, Ehime, Japan. npnsr835@yahoo.co.jp
authors: Koji
authors: K
authors: Nagatani
authors: Rie
authors: R
authors: Yamaoka
authors: Yuko
authors: Y
authors: Tezuka
authors: Masatoshi
authors: M
authors: Hayashi
mesh_terms: D018941:Antigens, CD19 / Q000378:metabolism*; D016175:B-Lymphocyte Subsets / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D018956:CD5 Antigens / Q000378:metabolism*; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000276:immunology
chemical_list: D018941:Antigens, CD19; D015415:Biomarkers; D018956:CD5 Antigens; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D009173:Mycophenolic Acid